Clinical rate and duration of response for RAI-refractory well-differentiated thyroid cancer #hncs16

Dr. Keith C. Bible, MD or the Mayo Clinic discusses the clinical benefit rate and duration of response for first and second line therapy in RAI-refractory well-differentiated thyroid cancer at ASTRO Head and Neck Symposium